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ABSTRACT
Introduction: The Assessments of SpondyloArthritis
international society Health Index (ASAS HI) measures
functioning and health in patients with
spondyloarthritis (SpA) across 17 aspects of health
and 9 environmental factors (EF). The objective was
to translate and adapt the original English version of
the ASAS HI, including the EF Item Set, cross-
culturally into 15 languages.
Methods: Translation and cross-cultural adaptation
has been carried out following the forward–backward
procedure. In the cognitive debriefing, 10 patients/
country across a broad spectrum of
sociodemographic background, were included.
Results: The ASAS HI and the EF Item Set were
translated into Arabic, Chinese, Croatian, Dutch,
French, German, Greek, Hungarian, Italian, Korean,
Portuguese, Russian, Spanish, Thai and Turkish.
Some difficulties were experienced with translation of
the contextual factors indicating that these concepts
may be more culturally-dependent. A total of 215
patients with axial SpA across 23 countries (62.3%
men, mean (SD) age 42.4 (13.9) years) participated in
the field test. Cognitive debriefing showed that items
of the ASAS HI and EF Item Set are clear, relevant
and comprehensive. All versions were accepted with
minor modifications with respect to item wording and
response option. The wording of three items had to
be adapted to improve clarity. As a result of cognitive
debriefing, a new response option ‘not applicable’
was added to two items of the ASAS HI to improve
appropriateness.
Discussion: This study showed that the items of the
ASAS HI including the EFs were readily adaptable
throughout all countries, indicating that the concepts
covered were comprehensive, clear and meaningful in
different cultures.
INTRODUCTION
The Assessments of SpondyloArthritis inter-
national society Health Index (ASAS HI),
published in 2014, is a unidimensional
Key messages
What is already known about this subject?
▸ The Assessments of SpondyloArthritis inter-
national society Health Index (ASAS HI) question-
naire has been developed in English-speaking
countries worldwide to assess functioning and
health in patients with ankylosing spondylitis.
What does this study add?
▸ Translation and cross-cultural adaptation of the
ASAS HI into 15 languages in 23 countries
showing good performance in different cultures
in patients with axial and peripheral
spondyloarthritis.
How might this impact on clinical practice?
▸ Functioning and health in patients with axial
spondyloarthritis can be assessed in clinical
trials and in daily routine by using one of the
disease-specific ASAS HI versions covering
most of the languages worldwide.
Kiltz U, et al. RMD Open 2016;2:e000311. doi:10.1136/rmdopen-2016-000311 1
Spondyloarthritis
questionnaire measuring functioning and health in
patients with ankylosing spondylitis (AS).1 Consistent
with the biopsychosocial model of health, the ASAS HI
includes a multidimensional item set assessing the rele-
vant contextual environmental factors (EF Item Set). AS
is a chronic inﬂammatory rheumatic disease and is char-
acterised by signs of sacroiliitis on plain radiograph.2
Recently, patients with similar symptoms and signs as AS,
with and without radiographical changes can be classi-
ﬁed as axial spondyloarthritis (axSpA).3 Since axSpA
usually starts in early adulthood, the lifetime impact of
the disease on functioning and health can be substantial
because of pain, stiffness, fatigue and limitations in activ-
ities and social participation.4–6 As no agreement on an
objective clinical deﬁnition of the severity of AS was
reached among expert members of ASAS it was chosen
to assess severity using a patient-reported outcome.
The ASAS HI and the EF Item Set measure function-
ing and health across many aspects of health that are
typical and relevant for patients with AS. It is based on
the Core Set of AS which was derived from the
International Classiﬁcation of Functioning and Health
endorsing the biopsychosocial framework of health.7
The ASAS HI contains items addressing categories of
pain, emotional functions, sleep, sexual function, mobil-
ity, self-care and community. The items form a unidi-
mensional scale providing a sum score representing
different levels of functioning. The EF Item Set contains
items addressing categories of support/relationships,
attitudes and health services. These EF items can act as
a barrier or a facilitator and they may inﬂuence the
health of patients.8
The ASAS HI was originally developed in ﬁve English
speaking countries (Australia, Canada, Ireland, UK and
USA). To support the distribution and use in different
countries, ASAS members were asked to participate in
an international translation project to develop validated
and reliable additional language versions.
The aim of this paper is to describe the translation and
cultural adaptation of the ASAS HI and the EF Item Set
into 15 languages across 23 countries among patients with
radiographic and non-radiographic axSpA (nr-axSpA).
METHODS
The ASAS HI contains 17 items with a dichotomous
response option indicating “I agree” and “I do not
agree” (see online supplementary material 1). The total
sum of the ASAS HI ranges from 0 to 17, with a lower
score indicating a better health status. The EF Item Set
contains nine dichotomous items with identical response
option (see online supplementary material 2) but
without a sum score because of its multidimensional
nature. Translation and cross-cultural adaptation of the
English version was carried out using the forward–back-
ward procedure, which consists of ﬁve steps:9
1. Translation: Two independent translations into target
language by an informed and an uninformed
translator, both bi-lingual but native speaker of the
target language
2. Synthesis: Synthesis of the two translations
3. Back translation: Create two back translations based
on the ﬁrst two translations by translators blinded for
the original version
4. Expert committee review: Review all reports, reach
consensus on discrepancies, produce a preﬁnal
version
5. Field test with cognitive debrieﬁng: Test complete
questionnaire in the target language in a small group
of relevant patients or lay people in order to test
alternative wording and to check understandability,
interpretation and cultural relevance of the
translation.
The investigator were informed to use for item 2, 4, 9,
10, 11, 13 and 14 the validated country-speciﬁc translation
because those items were derived from existing question-
naires (Ankylosing Spondylitis Quality of Life (ASQoL)
(item 13 and 14), Health Assessment Questionnaire
(HAQ) (item 10), Nottingham Health Proﬁle (NHP)
(item 2 and 9), Rheumatoid Arthritis Quality of Life
(RAQoL) (item 4 and 11). Participating countries were
selected based on their interest in research in axSpa. A
national subinvestigator was appointed, who was provided
with a description of the methodology including literature
about cross-cultural adaptation and a standardised operat-
ing procedure describing the setting of the ﬁeld test.9 10
The different steps of the translation had to be documen-
ted in a written document to ensure transparency and
comparability. Forward and backward translations were
performed for 15 languages in 20 countries (Austria,
Belgium, China, Colombia, Croatia, Egypt, France,
Germany, Greece, Hungary, Italy, Korea, Mexico, Portugal,
Russia, Spain, Switzerland, Thailand, the Netherlands,
and Turkey). For languages spoken in more than one
country (Dutch/Flemish, German and Spanish), the
national subinvestigators worked together and were free to
decide to harmonise one translation or to proceed with
translational steps by using country-speciﬁc versions. Each
reconciled translation was reviewed by UK and discussed
with the steering committee (AB, JB and DvdH).
The cognitive debrieﬁng was conducted in 4 English
(Australia, Canada, UK and USA) and 18 non-English-
speaking countries (all centres which participated in the
translation except for Austria and Switzerland). Adult
patients with axSpA were eligible for participation in the
exercise. At least 10 patients (60% AS and 40% nr-axSpA)
per country are needed to participate in the ﬁeld test.
Attention was paid to include in this convenient sample
patients across a broad spectrum of sociodemographic
background (age, gender and education) focusing on
patients with lower education (as recorded by number of
years of formal education). First, patients completed the
ASAS HI and the EF Item Set in the presence of an inter-
viewer and the completion time for the ASAS HI and EF
Item Set was recorded. Afterwards patients underwent a
structured interview focusing on skipped or missing items,
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potential ambiguous and inappropriate items. Patients
were asked by the interviewer to comment on the items of
the questionnaires, the instructions and the response
format by using open questions and documenting the
response as direct quotations. The information of the cog-
nitive debrieﬁng was documented in a semistructured
written report by responding to predeﬁned questions and
the possibility to document the thoughts of the patients.
The cognitive debrieﬁng interview aimed to test the rele-
vance, acceptability and comprehensiveness of the trans-
lated ASAS HI and the EF Item Set and its applicability in
patients representing the entire clinical spectrum of axSpA.
All centres received approval from the responsible ethics
committees. Written informed consent was obtained from
all respondents prior to the start of the study. Each country
provided the ﬁndings of the cognitive debrieﬁng in a
written report and the results were analysed descriptively.
RESULTS
The ASAS HI and EF Item Set were successfully trans-
lated into 15 languages: Arabic, Chinese, Croatian,
Dutch/Flemish, French, German, Greek, Hungarian,
Italian, Korean, Portuguese, Russian, Thai and Turkish
as well as three different versions of the Spanish lan-
guage (Colombia, Mexico and Spain). Since some items
included in the ASAS HI had been derived from other
validated questionnaires for which translation was
already available (eg, ASQoL, HAQ, NHP, RAQoL), the
items of the validated translations were used for items 2,
4, 9, 10, 11, 13 and 14.1 Furthermore, emphasis was on
conceptual rather than linguistic translations so that
some of the translated items could take a different form
compared to the original version.
ASAS Health Index: Most of the 17 items and the instruc-
tions of the ASAS HI were translated into all 15 languages
without difﬁculties. The translation of the word
“running” in item 3 and “exhausted” in item 5 of the
ASAS HI caused linguistic problems because in some lan-
guages the word has different meanings (‘running’)
(Dutch, German) or does not exist as such (‘exhausted’)
(Korean, Thai). Discrepancies were solved by discussions
in the translation teams with support by ASAS providing
the background information for the item. Item 4 was
cross-culturally adapted by emphasising that “problems
using toilet facilities” is the main content of this item.
Environmental Factor Item Set: Difﬁculties were experi-
enced with translation of the contextual factors indicating
that these concepts may be more culture-dependent. The
translation of item 2 “friends act around me” and item 6
“treatment is taking up time” was challenging because of
misunderstanding of the underlying concepts.
Discrepancies were solved by discussion and providing
the background of these items to the translation team.
Item 4 (“modify environment”) raised concerns because
the relation to the speciﬁc setting was not clear enough
and therefore the item was speciﬁed to “modify home
and work environments” in all languages.
In the ﬁeld test, 215 patients (mean age 42.4±13.9,
range 18–86 years, 62.3% men) in 22 countries (∼10
patients/country) with axSpA underwent a cognitive
debrieﬁng interview. A total of 140 patients (65.1%)
were diagnosed with AS and 75 patients (34.8%) pre-
sented as nr-axSpA. Altogether, 71 patients (33.0%) suf-
fered from peripheral involvement in this cohort with a
disease duration of 11.2±11.0 (range 0–53) years. We
noticed a moderate disease activity with a BASDAI of 3.8
±2.3 (range 0–9.6). Altogether, 117 patients (56.6%)
included in the cohort were employed, whereas unpaid
work was due to disability (n=35), retirement (n=16),
homemaker (n=15), student (n=12) and job seeking
(n=10). Formal education varied between 4 and 22 years
with a mean of 13.3±3.8. The country-speciﬁc details are
listed in table 1 and table 2.
About 95% of interviews showed that the English ques-
tionnaire and the translations were clear, appropriate,
relevant, comprehensive and easy to complete in the dif-
ferent cultures. However, we received comments on
some items, especially item 7 (“I lost interest in sex”)
and item 8 (“I have difﬁculty operating the pedals in my
car”). These items of the ASAS HI were discussed fre-
quently because some patients either could not or did
not want to answer the questions. As a result of the dis-
cussion, a new response option ‘not applicable’ was
added to the ASAS HI for items 7 and 8. In the EF Item
Set, the phrasing of item 6 (“getting relapses acknowl-
edged by a health professional”) was not clear enough
for the patients so that the original version and the
translations were changed to the wording “worsening of
my disease”. All translations were accepted with minor
modiﬁcations.
The total score of the ASAS HI was 7.1±4.4 (mean±SD,
range 0–17). Completion times for ASAS HI and for EF
Item Set were short with 2.6±1.6 and 2.1±1.5 (mean±SD)
minutes, respectively. The country-speciﬁc details are
listed in table 1 and table 2. All versions are available free
for use and they can be downloaded from the ASAS
homepage, section clinical instruments (http://www.
asas-group.org/clinical-instruments.php?id=03).
The patients were asked to mention concepts which
are important for them but are not represented by the
17 aspects of the ASAS HI. Ten percent of the patients
expressed that they missed concepts which included the
following themes: medication, being able to perform
sports, impaired vision, shortness of breath, sitting for a
long time, depression, pregnancy and psychological
issues such as patients concealing their disease from col-
leagues and friends (each <5%).
DISCUSSION
The ASAS HI and the EF Item Set were successfully trans-
lated in parallel into 15 languages with 17 versions (see
http://www.asas-group.org, English version see online
supplementary 1 and 2). The ﬁeld test interviews show
that the ASAS HI and the EF Item set have high face and
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Table 1 Characteristics of patients taking part in the field test in each of the European countries
Belgium
n=9
Croatia
n=10
France
n=7
Germany
n=10
Greece
n=10
Hungary
n=10
Italy
n=10
Nether lands
n=11
Portugal
n=10
Russia
n=10
Spain
n=7
Turkey
n=10 UK n=11
Age (years), mean (SD) 35.0 (8.1) 46.0 (12.3) 45.0 (11.2) 43.7 (17.5) 37.9 (13.0) 59.8 (10.1) 44.1
(16.6)
49.2 (18.6) 41.4 (13.7) 32.8 (12.0) 49.0
(10.5)
38.4 (12.4) 40.4
(16.0)
Gender, male (%) 67 30 14 50 80 70 60 45 80 60 71 40 73
Disease subtype, AS (%) 56 60 50 70 80 60 60 64 60 60 67 60 70
Disease duration (years),
mean (SD)
6.8 (3.8) 7.3 (7.1) 9.0 (6.0) 8.7 (9.4) 12.7 (12.4) 11.5 (11.7) 6.8 (8.0) 14.7 (15.0) 8.9 (10.7) 25.3 (9.7) 15.7
(13.8)
6.8 (7.3) 8.1 (8.9)
Working status, paid work (%) 78 70 43 50 70 20 60 27 70 50 57 30 55
Education (years), mean (SD) 14.3 (3.4) 13.7 (2.2) 10.0 (9.5) 15.9 (2.6) 16.0 (1.6) 10.9 (3.9) 14.7 (3.6) 9.0 (2.9) 12.3 (2.9) 13.6 (3.4) 16.3 (5.1) 10.2 (4.3) 13.5 (2.5)
ASAS HI, mean (SD) 3.6 (3.8) 12.1 (5.9) 8.0 (2.8) 4.9 (1.9) 5.3 (2.7) 9.5 (4.8) 6.7 (3.4) 5.1 (3.7) 5.1 (4.0) 7.9 (4.3) 4.7 (3.9) 6.4 (3.4) 6.0 (4.2)
ASAS HI, range (0–17) 0–10 2–17 3–11 2–8 2–10 0–15 0–13 0–11 1–13 1–16 0–12 1–11 0–14
BASDAI, mean (SD) 2.6 (2.0) 5.7 (1.7) 4.6 (1.6) 3.5 (1.9) 2.2 (1.8) 3.7 (3.0) 3.4 (1.4) 3.8 (1.8) 3.6 (2.3) 3.8 (3.0) 2.2 (1.6) 3.1 (2.0) 4.6 (2.8)
BASDAI, range (0–10) 0.5–6.7 3.1–8.0 2.9–7.5 1.0–6.5 0.3–4.8 0.4–9.6 2.0–5.8 1.3–6.5 0.8–8.2 0–8.4 0.2–4.8 0.6–6.1 2.1–9.4
AS, ankylosing spondylitis; ASAS HI, ASAS Health Index; BASDAI, Bath Ankylosing Spondylitis Disease Activty Index.
Table 2 Characteristics of patients taking part in the field test in each of the non-European countries
Australia
n=10
Canada
n=10
China
n=10
Colombia
n=10
Egypt
n=10
Korea
n=10
Mexico
n=10
Thailand
n=10 USA n=10
Age (years), mean (SD) 43.5 (19.8) 45.9 (13.4) 27.8 (12.2) 45.9 (8.8) 37.3 (14.7) 34.8 (11.0) 36.8 (9.4) 42.8 (12.6) 51.6
(12.5)
Gender, male (%) 80 60 100 50 60 90 60 50 70
Disease subtype, AS (%) 60 80 60 60 50 60 60 100 80
Disease duration (years), mean
(SD)
21.9 (7.6) 11.9 (13.5) 2.7 (4.5) 5.7 (4.2) 9.3 (7.7) 3.0 (1.8) 12.9 (8.9) 9.5 (6.9) 18.3
(19.1)
Working status, paid work (%) 60 70 40 60 90 30 90 60 30
Education (years), mean (SD) 13.5 (3.7) 13.9 (1.7) 14.2 (8.5) 13.8 (2.1) 14.9 (4.0) 11.7 (3.6) 13.3 (5.5) 13.1 (4.5) 15.8 (3.7)
ASAS HI, mean (SD) 5.7 (2.7) 8.2 (4.3) 6.1 (5.0) 12.6 (2.7) 6.0 (3.6) 7.4 (5.1) 9.2 (3.9) 6.5 (4.7) 8.4 (4.2)
ASAS HI, range 2–10 0–16 0–15 7–16 0–11 0–14 3–15 1–14 2–15
BASDAI, mean (SD) 3.4 (2.3) 4.5 (2.8) 3.0 (2.4) 5.9 (2.0) 3.9 (2.3) 3.5 (2.0) 4.0 (1.9) 3.2 (1.9) 5.3 (2.2)
BASDAI, range 2–10 1.2–8.7 0.2–7.0 1.8–8.4 1.2–8.1 0.4–7.4 0.2–6.6 0.6–6.3 0.7–8.4
AS, ankylosing spondylitis; ASAS HI, ASAS Health Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index.
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content validity, both with a short time to complete the
questionnaire. The English and the translated versions
were found to be clear, comprehensive and acceptable to
patients in all countries. The simultaneous process of
translation and cultural adaptation into several languages
is beneﬁcial in order to facilitate effective implementation
of the ASAS HI into daily practice.
This study also showed that the items were readily
adapted across countries, indicating that the concepts
covered are meaningful for many different cultures.
Minor linguistic problems were solved and a new
response option for two items was added to address the
needs of the patients.
The knowledge about other disease manifestations
apart from AS was limited in the development process of
the ASAS HI which started in 2009. As a result of the
new classiﬁcation criteria, the characteristics of this dis-
order have changed and the applicability of this new
outcome measure was warranted for the whole SpA spec-
trum.3 We were able to show in the cognitive debrieﬁng
interviews that face and content validity was covered
both for patients with AS and nr-axSpA, irrespective of
peripheral involvement or not. The involvement of a
broad spectrum of patients with axSpA has contributed
to preliminarily validate the ASAS HI and the EF Item
Set for the whole spectrum of patients with axSpA.
Further studies are needed to fully validate the ques-
tionnaires. An international validation study will help to
conﬁrm the discriminative ability and responsiveness in
a larger patient group. This ongoing project will be an
important step for the implementation of the ASAS-HI
and the EF Item Set into clinical practice on an inter-
national level and more translations will be produced in
the mean time.
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